WHO
REGULATORY UPDATE
Cipla’s Nirmatrelvir + Ritonavir and Getz’s Moxifloxacin tablet products prequalified
Published: 11/4/2026Detected: 11/4/2026
Summary preview
Adds two new manufacturers’ tablet products to the WHO Prequalification Programme list: Cipla’s co-blistered nirmatrelvir/ritonavir for higher-risk non-severe COVID-19, and Getz Pharma’s moxifloxacin for use in…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountinfectious_disease
respiratory
manufacturing
quality
clinical
safety
labeling
#WHO prequalification
#PQT
#nirmatrelvir
#ritonavir
Official Source Document Source Verified
Access the original document directly from WHO.
More from WHO
- Invitation to a Webinar on managing reportable changes11/4/2026
- New Deadline for Submission: Request for Quotations (RFQ) from interested Notified Bodies - WHO Prequalification Assessment for Medical Devices11/4/2026
- PQT/AMD newsletter - Q3 2026, Issue 54 is now available11/4/2026
- PQ Webinar: Launch of WHO Prequalification of Medical Devices11/4/2026
- VCP Updates - October 202611/4/2026